Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine whether changes in uptake of [18F]DCFPyL PET/CT scans at baseline and after
6 weeks of treatment for metastatic castrate resistant prostate cancer, correlates with
radiographic progression free survival (rPFS) as defined by Prostate Cancer Working
Group 3 (PCWG3) criteria.
Secondary Objectives:
- To determine whether changes in uptake of [18F]DCFPyL PET/CT scans correlate with
overall survival (OS)
- To determine whether baseline SUVmax correlate with rPFS
- To compare number of lesions detected with standard imaging at baseline and at the time
of progression